MAPT and Alzheimer disease: CMA was reported to be suppressed at an early stage of AD and its activation could reduce the levels of Aβ plaques and tau phosphorylation, and ameliorate behavioral phenotype (Dou et al., 2020; Bourdenx et al., 2021; Xu X. et al., 2021; Caballero et al., 2021).